BIOTRONIK Launches Innovative New Tachycardia and Heart Failure Solutions in Japan
Acticor 7 ICDs and CRT-Ds Provide Extended Battery Life and MR Conditionality in a Smaller Device
BIOTRONIK today announced the launch of its Acticor 7 ICD and CRT-D families, which offer a variety of features that specifically address the needs of Japanese patients. The devices are only 10 mm slim and come with an elliptical BIOshape as well as longer battery life.
“The new thinner Acticor 7 devices with improved size and shape better suit the needs of patients in the Asian population,” said Dr. Jun Kishihara, Kitasato University Hospital, Japan. “This not only simplifies the insertion procedure for physicians but also improves patients’ comfort at the site of implantation on the chest.”
Despite their smaller size and ultraslim shape, Acticor 7 devices feature an extended battery life, with 15 years for ICDs1 and nine years for CRT-Ds2. These longevities also include daily cardiac device data transmissions via BIOTRONIK Home Monitoring®.
Japan was one of the first countries in Asia Pacific to adopt remote monitoring on a large scale and the demand for remote cardiac care remains high. Supporting this adoption clinical evidence such as the IN-TIME study has shown more than a 60% reduction in all-cause mortality for CRT-D patients when monitored with BIOTRONIK Home Monitoring.3 With ICDs, Home Monitoring has demonstrated a 90% reduction in inappropriate shocks and a 73% reduction in related hospitalization rates.4
“The combination of BIOTRONIK Home Monitoring and MRI compatibility also provides a significant advantage for patient management post implantation,” Dr. Jun Kishihara pointed out. All Acticor 7 devices feature ProMRI, giving patients full access to high-resolution 3 Tesla MRI scans without any exclusion zone.
Acticor 7 CRT-Ds feature CRT AutoAdapt to fit patients’ individual pacing needs and provide continuous CRT adaptation – automatically adjusting to changes sensed in a patient’s condition every minute. Auto LV VectorOpt further helps to evaluate clinically relevant pacing parameters, with automatic threshold measurements across 20 vectors5 in less than 2.5 minutes6 and rapid direct programming.
“These devices are the result of extensive feedback from the Japanese market to our development team in Berlin,” explained Jeffrey Annis, Managing Director, BIOTRONIK Japan. “The improvements made in Acticor 7 will provide physicians an additional tool to better support the overall care of patients here in Japan for the future.”
1. Acticor/Rivacor VR-T Standard conditions. 15.4 years @ 40 ppm; 0% pacing @ 2.5V/0.4ms; 500 Ohms; 2 max. energy shock/year. Data on file.
2. Acticor/Rivacor HF-T QP, 9.3 years @ 60 ppm; RA 15%, RV/LV 100% pacing, RA/RV/LV @ 2.5 V/0.4 ms; 500 Ohms, 2 max. energy shocks/year. Data on file.
3. Hindricks G et al. Implant-based multiparameter telemonitoring of patients with heart failure (IN-TIME): a randomised controlled trial. The Lancet. 2014; 384(9943): 583-590.
4. Guedon-Moreau L et al. Decreased delivery of inappropriate shocks achieved by remote monitoring of ICD: a substudy of the ECOST trial. J Cardiovasc Electrophysiol. 25(2014): 763-770.
5. QP models only.
6. Post-Market observation; final-report, March 1, 2019. Data on file.
At BIOTRONIK, patient well-being is our top priority and has been for 60 years. BIOTRONIK is a leading global medical technology company with products and services that save and improve the lives of millions suffering from heart and blood vessel diseases. Driven by a purpose to perfectly match technology with the human body, we are dedicated innovators who develop trusted cardiovascular and endovascular solutions. BIOTRONIK is headquartered in Berlin, Germany, and is represented in over 100 countries.